Novartis Bolsters NASH Pipeline with a Deal with Conatus

By Subham Nandi

Pharma Deals Review: Vol 2017 Issue 1 (Table of Contents)

Published: 18 Jan-2017

DOI: 10.3833/pdr.v2017.i1.2218     ISSN: 1756-7874

Section: Licensing



Novartis adds heat to the highly competitive non-alcoholic steatohepatitis (NASH) market with a deal with Conatus Pharmaceutical to co-develop emricasan, an oral first-in-class pan-caspase inhibitor being evaluated for NASH fibrosis and cirrhosis in a deal worth US$722 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details